<![CDATA[The journey to personalize breast cancer therapy increasingly navigates the complex landscape of somatic TP53 mutations, the most frequent genetic drivers of this disease. Moving beyond a simple prognostic badge, we now understand these mutations create a spectrum of clinical behaviors, deeply influenced by their specific functional impact and, critically, by their genetic companions. A systematic literature review was conducted across three major electronic databases: ScienceDirect, ProQuest, and Scopus. The search was restricted to peer-reviewed journal articles published in English between 2021 and 2024 to ensure the inclusion of recent evidence. The confluence of TP53 and PIK3CA mutations stands out as a devastating synergy that heralds a tumor phenotype with profound resistance to common chemotherapy regimens, especially taxanes, and the direst survival outcomes. This genetic context also subtly reshapes responses to HER2-targeted drugs, revealing that TP53's influence is both powerful and context-dependent. A more nuanced profiling, one that accounts for these critical genetic interactions, is no longer a future aspiration but a present necessity. These findings collectively advocate for the integration of comprehensive molecular profiling, including nuanced TP53 and PIK3CA assessment, into clinical decision-making.]]>
Copyrights © 2026
